Introduction
Phospholipases A 2 (PLA 2 s) catalyze the hydrolysis of the sn-2 ester bond of glycerophospholipids to generate free fatty acids and lysophospholipids (Schaloske and Dennis, 2006; Lambeau and Gelb, 2008) . Over the past few years, it has been realized that PLA 2 s constitute a superfamily of enzymes comprising several intracellular enzymes and secreted PLA 2 s (sPLA 2 s).
The group IVA cytosolic PLA 2 (cPLA 2 α) is the best known intracellular PLA 2 , and it clearly plays an important, yet not exclusive role in the release of arachidonic acid (AA) and subsequent production of eicosanoids in various biological settings (Kita et al., 2006) . On the other hand, the biological functions of the different sPLA 2 s are slowly being unraveled. sPLA 2 s have been implicated in lipid digestion and obesity, activation of immune cells, asthma, atherosclerosis, acute respiratory distress syndrome, and host defense against bacteria, viruses and parasites (Touqui and Wu, 2003; Triggiani et al., 2006; Lambeau and Gelb, 2008; Nevalainen et al., 2008 ) . Besides their catalytic activity, sPLA 2 s are also able to bind to specific soluble and membrane binding proteins including the M-type receptor (Rouault et al., 2007) . Several PLA 2 s have also been implicated in various cancers. Disruption of the cPLA 2 α gene decreases initiation and growth of intestinal tumors in Apc mutated mice (Takaku et al., 2000) , but increases the number of tumors in the carcinogen azoxymethane-induced mouse model of colon cancer (Ilsley et al., 2005) . The gene coding for mouse group IIA (mGIIA) sPLA 2 was identified as a gene modifier that reduces the number of intestinal polyps in Apc +/Min mice, but the mechanism of action is still unclear (Fijneman and Cormier, 2008) . Distinct roles have also been proposed for human group IIA sPLA 2 in various cancers (Sved et al., 2004; Cummings, 2007) . Recent data have shown differential expression of sPLA 2 s IID, III, and V, but not X in human colon cancer . In Apc ∆ 716 and azoxymethane mouse models of colon cancer, the expression of group X sPLA 2 may be increased in small intestinal tumors, but not in colon tumors (Takaku et al., 2000; Ilsley et al., 2005) . In vitro, group IB, IIA and III sPLA 2 s have been reported to stimulate cell proliferation and activation of MAP kinases in various cancer cells (Kinoshita et al., 1997; Sved et al., 2004; Murakami et al., 2005) . Finally, subcutaneous injection into nude mice of This article has not been copyedited and formatted. The final version may differ from this version. colon tumor cells overexpressing mGIIA sPLA 2 resulted in a 2.5-fold increase in tumor size (Belinsky et al., 2007) .
Over the past few years, the group X sPLA 2 has appeared as the most potent sPLA 2 capable of hydrolyzing phosphatidylcholine and acting extracellularly on cellular membranes and non cellular phospholipid substrates such as lipoproteins (Lambeau and Gelb, 2008) . Consequently, group X sPLA 2 has been proposed to play a role in atherosclerosis (Lambeau and Gelb, 2008) , asthma (Henderson et al., 2007) and colon cancer (Morioka et al., 2000) .
The above findings plus the fact that group X sPLA 2 is expressed at very high levels in human (Cupillard et al., 1997; Morioka et al., 2000; and mouse colon ( (Eerola et al., 2006 ) and this study) prompted us to analyze the proliferative effect of group X sPLA 2 on different colon cancer cells including the adenocarcinoma-derived mouse Colon-26 cancer cells. Among different mouse sPLA 2 s, group X sPLA 2 was the most potent enzyme to stimulate cell proliferation.
Using a combination of tools and methods, we found that its proliferative effect does not depend on binding to the M-type receptor or activation of cPLA 2 α, but rather on its intrinsic catalytic activity and ability to release free fatty acids and lysophospholipids, which most likely act in concert to stimulate cell proliferation.
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-7-sPLA 2 expression in mouse intestinal tract analyzed by RT-qPCR. Tissue samples from duodenum, jejunum, ileum, and proximal and distal colon from two C57BL/6J female or three BALB/c female mice were snap-frozen in liquid nitrogen. Total RNA was isolated using the Nucleospin RNA extraction kit with DNase I treatment and Lysing Matrix D beads to homogenize the samples. Reverse-transcription and real-time quantitative PCR (RT-qPCR) were performed as described (Eerola et al., 2006) . The abundance of each sPLA 2 mRNA target was calculated relative to the expression of GAPDH mRNA which was used as a reference gene. The tissue distribution of sPLA 2 s and cPLA 2 α was further normalized to the lowest Ct value accurately measured. A relative abundance of 1 (arbitrary unit = 1) was assigned to the expression level of the pancreatic group IB sPLA 2 mRNA in the colon which was detected with Ct values of 33 or higher. Standard deviation calculation was made according to the User Bulletin #2 from ABI.
Expression of mGX sPLA 2 by in situ hybridization. Samples for in situ hybridization were obtained from small and large intestines of C57BL/6J mice, fixed in 4% phosphate-buffered formalin and embedded in paraffin. A 0.45 kb mGX sPLA 2 cDNA insert was cloned into the pRc/CMV vector (Invitrogen) and used as a template to prepare digoxigenin (DIG)-labeled antisense (test) and sense (control) RNA probes by in vitro transcription using a commercial kit (DIG RNA labeling kit, Roche Diagnostics, Meylan, France) according to the manufacturer's instructions. Non radioactive in situ hybridization has been described in detail previously (Haapamaki et al., 1999) . Briefly, 5-μm-thick paraffin sections were placed on silanated slides, dewaxed in xylene and rehydrated in a graded alcohol series. Pretreatment was performed sequentially with 200 mM HCl for 20 min, 20 μ g/ml proteinase K at 37°C for 15 min, 0.2 % glycine in phosphate-buffered saline (pH 7.4) two times 3 min, freshly prepared 0.4% acetic anhydride in 100 mM triethanolamine two times 5 min, and finally with ficin (Zymed Digest-All Kit, San Francisco, CA) at 37°C for 20 min. The sections were then blocked in hybridization solution without probe. The solution was replaced with fresh hybridization solution containing the antisense or sense probe at a final concentration of 60 ng/ml. After overnight hybridization, the sections were washed in 2 X saline-sodium citrate (SSC) for 5 min, 0.2 X SSC, 60%
formamide at 37°C three times 5 min and 2 X SSC two times 5 min. The sections were blocked with This article has not been copyedited and formatted. The final version may differ from this version. 3% bovine serum albumin in tris-buffered saline and the hybridized probe detected with alkaline phosphatase-labeled anti-DIG Fab-fragments (1/2,000; Roche) using a substrate solution containing 0.18 mg/ml 5-bromo-4-chloro-3-indolyl-phosphate, 0.34 mg/ml 4-nitroblue tetrazolium phosphate (NBT/BCIP, Roche) and 0.24 mg/ml levamisole (Vector, San Francisco, CA) in 100 mM Tris pH 9.5, 100 mM NaCl and 50 mM MgCl 2 . The color reaction was allowed to develop at 4°C overnight and at 25°C for 6 h. The tissue sections were briefly counterstained with hematoxylin, washed with water and mounted in aqueous mounting medium.
Cell culture. Colon-26 cells were grown at 37°C in DMEM/10% FCS, antibiotics, and 2 mM glutamine. AJ02-nm0 cells were grown in RPMI/10% FCS with antibiotics, glutamine and supplementation with insulin (6.25 ng/ml), transferrin (6.25 µg/ml) and selenious acid (6.25 ng/ml) (ITS). YAMC and Apc +/Min cells express the temperature-sensitive mutation of the simian virus 40 large tumor antigen gene (tsA58) and grow well at 33°C but become quiescent at 37°C. YAMC cells were grown at 33°C in RPMI supplemented with 5% FCS, antibiotics, ITS, and 5 U/ml recombinant IFNγ. Apc +/Min cells were grown at 33°C in DMEM supplemented with 10% FCS, antibiotics, 10 U/ml recombinant IFNγ and 10 ng/ml recombinant EGF. We found that these cells do not release sPLA 2 enzymatic activity in cell medium during their normal growth, nor express detectable amounts of mGX sPLA 2 protein by time-resolved fluoroimmunoassays (Eerola et al., 2006) . To determine whether these cell lines express or not a functional mGIIA sPLA 2 gene (MacPhee et al., 1995) , we set up conditions for the specific detection of wild-type and mutated mGIIA alleles by PCR on genomic DNA (see supplemental data). YAMC cells were found to be heterozygous for the pla2g2a gene,
Colon-26 cells were found to be wild-type while AJ02-nm0 and Apc +/Min cells were found to contain two mutated pla2g2a alleles (supplemental Fig. 1S ). r(UUAAUGUAUCGAGUGUACC)dTdA) and cPLA 2 α (Forward : r(GGA GAU UAA UGA AGA GCU A) dTdT Reverse : r(UAG CUC UUC AUU AAU CUC C)dTdC) were compared with the effect of the non relevant GFP-directed siRNA (Forward : GCA AGC UGA CCC UGA AGU UCA U, Reverse : GAA CUU CAG GGU CAG CUU GCC G).
Binding assays and immunocytochemistry. The expression of the mouse M-type receptor in various cell lines was determined by binding experiments using iodinated OS 1 as described (Rouault et al., 2007 Eicosanoid assays. Colon-26 cells (10 6 cells) were grown in 6-well culture plates for 2 days, starved for 24 h and stimulated for 24 h with 200 nM mGX sPLA 2 in 1 ml of serum-free medium containing 0.02% FAF BSA. Total eicosanoid production in combined supernatant and cell pellet was assayed by HPLC/MS following the procedure described previously (Kita et al., 2005; Henderson et al., 2007) . For specific PGE 2 assay, cell supernatants from proliferation assays were centrifuged, appropriately diluted (1/10 to 1/500) and PGE 2 levels were determined using the PGE 2 enzyme immunoassay kit (Assay Designs) according to the manufacturer's instructions.
Lysophospholipid analysis. Colon-26 cells (2.10 6 cells) were seeded in 10-cm Petri dishes and grown for 2 days, then starved for 24 h in FCS-free medium/0.02% FAF BSA and stimulated with effectors in 4 ml of FCS-free medium/0.02% FAF BSA for 6 and 24 h. After incubation, the cell This article has not been copyedited and formatted. The final version may differ from this version. supernatants were collected and lyophilized. The cell monolayer (about 10 7 cells) was scraped in PBS, centrifuged and stored as a dried pellet at -70°C. The following procedure was adapted from previously published methods of LPA analysis (Baker et al., 2001) . Lyophilized supernatants were resuspended in 0.5 ml Milli-Q water and cell pellets were thawed on ice in 0.5 ml Milli-Q water. To each sample, 1.5 ml of 30 mM Citric Acid, 40 mM Na 2 HPO 4 (pH~4) was added and vortexed for 30 seconds. Samples were then spiked with 500 pmoles 17:0 LPA and 1 nmole d 31 -16:0 LPC and extracted using 4 ml of 1-Butanol followed by re-extraction with 2 ml of 1-Butanol. Organic phases were dried in vacuo overnight. The resulting residues were reconstituted in 1.5 ml 
Results
Group X sPLA 2 is expressed at high levels in mouse colon. We have recently found that mGX sPLA 2 is expressed at high levels in the small intestine and colon at both mRNA and protein levels (Eerola et al., 2006) . To further analyze the expression of mGX sPLA 2 and other PLA 2 genes in the different sections of the intestine of C57BL/6J mice, we have measured by RT-qPCR the relative abundance of mRNAs coding for the full set of mouse sPLA 2 s (except IIC), for cPLA 2 α (Fig. 1A ) and for the M-type receptor (not shown). Most sPLA 2 s were expressed in the different gut sections, but marked differences were found. Among catalytically-active sPLA 2 s, mGX sPLA 2 is by far the most highly expressed enzyme in the intestine of C57BL/6J mice, with highest expression in the distal colon. For instance, its level of expression in the colon is about 10-fold higher than that of mGV sPLA 2 . Interestingly, mGX sPLA 2 mRNA levels vary along the intestine with up to 120-fold increase in expression from duodenum to distal colon. Second, the levels of mRNA for the catalyticallyinactive group XIIB sPLA 2 -like protein are similar to those of mGX sPLA 2 , but the expression pattern is the inverse. Third, group IID, IIF, III and XIIA sPLA 2 s are expressed in the intestine at significant but low levels, and group IB and IIE sPLA 2 s are barely detectable. Expression of group XIIA sPLA 2 is rather constitutive all along the intestine. Conversely, that of group IIF, III, and V sPLA 2 s increases while that of group IID sPLA 2 decreases when moving from the proximal to the distal part of the gut.
Fourth, the expression of cPLA 2 α is 5-fold lower than that of mGX sPLA 2 , but follows a similar gradient of expression along the intestine. Finally, the expression of the M-type receptor was low along the gut sections (not shown), but interestingly follows the same gradient of expression of mGX sPLA 2 .
Importantly, C57BL/6J mice have a disrupted mGIIA sPLA 2 gene (MacPhee et al., 1995) , which likely explain the low and aberrant amount of mRNA observed in the small intestine (Fig. 1A) .
When RT-qPCR assays for the different sPLA 2 s were done as above on intestine sections from BALB/c mice expressing a functional gene, the expression of mGIIA sPLA 2 in jejunum and ileum was found to be much higher than that of all other sPLA 2 s including mGX sPLA 2 (Fig. 1B) . However, the This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 1B) .
To determine more precisely the cellular site of mGX sPLA 2 expression in small and large intestine, we performed in situ hybridization. Figs conditions of stimulation. This proliferative effect is important as it corresponds to about 50% of the maximal effect observed with fetal calf serum. We decided to use the Colon-26 cell line for the experiments described below because these cells are adenocarcinoma-derived and were easier to grow and transfect than the other cell lines. We also found that these cells do not express mGX sPLA 2 at the mRNA level by RT-qPCR analysis and at the protein level by both a highly specific and sensitive time-resolved fluoroimmunoassay (Eerola et al., 2006) and E. coli sPLA 2 enzymatic assays (data not shown). When compared to various mouse sPLA 2 s, we found that group X sPLA 2 has the strongest mitogenic capacity on Colon-26 cells (Fig. 3A) , and dose-dependently induced cell proliferation (Fig.   3B ). mGV and mGIIA sPLA 2 also significantly induced cell proliferation while the other sPLA 2 s were relatively poor inducers. To further demonstrate that group X sPLA 2 can trigger cell proliferation, we This article has not been copyedited and formatted. The final version may differ from this version. Fig. 3C , cells proliferated more rapidly over time in the presence of group X sPLA 2 . In accordance with their proliferative effects, both mGX and hGX sPLA 2 s were capable of inducing a time-dependent phosphorylation of p42/44 MAPK with a sustained induction at 4 h (Fig. 3D ).
Group X sPLA 2 stimulates the proliferation of Colon-26 cells via its catalytic activity and independently of binding to the M-type receptor. We next analyzed the molecular mechanisms involved in the proliferative effect of group X sPLA 2 . To evaluate the role of sPLA 2 enzymatic activity, we first used the specific sPLA 2 inhibitors Me-indoxam (Singer et al., 2002) and LY329722
(compound B in (Smart et al., 2006) ), which inhibit the catalytic activity of mGX sPLA 2 with IC 50 values of 500 nM and 75 nM, respectively. Both inhibitors clearly suppressed the proliferation and MAP kinase phosphorylation induced by mGX sPLA 2 (Figs. 4A and B). We then tested the mitogenic activity of catalytically-inactive mutants of mGX and hGX sPLA 2 s as well as of OS 2 , a snake venom sPLA 2 with high catalytic activity on phosphatidylcholine (Rouault et al., 2006) . The H48Q mutants of mGX and hGX sPLA 2 s have less than 0.1% of WT catalytic activity (not shown) and the D49K mutant of OS 2 is fully inactive (Rouault et al., 2006) . Results shown in Fig. 4C further demonstrates that the catalytic activity of group X sPLA 2 is required for its mitogenic effect. Finally, we evaluated the role of cPLA 2 α and found that the mitogenic effect of group X sPLA 2 on Colon-26 cells does not depend on cPLA 2 α activation as siRNA silencing of cPLA 2 α efficiently suppressed protein expression, but has little effect on the fold-increase factor of [ 3 H]-thymidine incorporation induced by hGX sPLA 2 (Fig. 4D) . However, our results also suggest that cPLA 2 α is involved in the proliferation of Colon-26 in the absence of exogenously added sPLA 2 since siRNA silencing slighly decreased the basal level of incorporation of [ 3 H]-thymidine (Fig. 4D ).
Since the M-type sPLA 2 receptor was previously proposed to play a role in cell proliferation (Kinoshita et al., 1997) and since both mGX and hGX sPLA 2 s bind to the mouse M-type receptor (Rouault et al., 2007) , we sought to determine whether this receptor is expressed in the above different colon cells and plays a role in the proliferative effect of group X sPLA 2 . We first screened the four colonic cell lines for the expression of the receptor using iodinated OS 1 , the snake venom sPLA 2 that This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 5D ). The specificity of siRNA silencing of the receptor was validated using a nonrelevant GFP-siRNA that did not suppress M-type receptor expression (Fig. 5C ). The capacity of group X sPLA 2 to increase Colon-26 proliferation was unaffected by knocking-down the M-type receptor, indicating that receptor binding is not required for the proliferative effect of group X sPLA 2 (Fig. 5D ). for 6 h (not shown) and 24 h (Fig. 6B) . Group X sPLA 2 increases the production of several eicosanoids, with PGE 2 being by far the most prominent eicosanoid product, with up to 74 ng/10 6 cells.
Group
This article has not been copyedited and formatted. The final version may differ from this version. In parallel experiments, we monitored the ability of group X sPLA 2 to release various lysophospholipids, namely LPA, LPC, LPE, LPG, LPI and LPS. We found that group X sPLA 2 can release a variety of lysophospholipids with different fatty acids at the sn-1 position from Colon-26 cells at 6 h ( Fig. 7) and 24h (not shown). The lysophospholipids produced in highest quantities were LPC and LPE, a result which is in accordance with the relative abundance of these lipids in cell membranes and the ability of group X sPLA 2 to efficiently hydrolyze zwitterionic phospholipids (Singer et al., 2002; Mitsuishi et al., 2007) . For instance, treatment with group X sPLA 2 for 6 hours led to 25-and 36-fold increases in the release of total LPC and LPE compared to untreated cells (Fig. 7A ).
Importantly, we also found that group X sPLA 2 increases by 3.7-fold the overall production of LPA.
The detailed data for production of the different acyl chain species for LPC and LPA are shown in Fig.   7B . They indicate for instance 41-and 26-fold increases for the two main products, oleoyl-LPC and palmitoyl-LPC.
Effects of various lipid mediators released by group X sPLA 2 on the proliferation of
Colon-26 cells. The above results led us to analyze the proliferative effect of each type of lipid mediators that are generated by the action of group X sPLA 2 . Since LPC can be further converted into lysophosphatidic acid (LPA) by autotaxin , we also tested the effect of LPA on cell proliferation. As shown in Fig. 8 (Fig. 8) . To test the hypothesis that PGE 2 production could explain at least in part the mitogenic effects of group X sPLA 2 , we treated Colon-26 cells with four non selective or COX-2 selective inhibitors (Aspirin, Indomethacin, Ibuprofen and Rofecoxib). We found that all four inhibitors were able to dramatically reduce PGE 2 production (Fig. 9A ), but were unable to suppress the cell proliferation induced by mGX sPLA 2 (Fig. 9B) . Interestingly, the COX inhibitors This article has not been copyedited and formatted. The final version may differ from this version. were also ineffective at suppressing the proliferative effect of free AA (Fig. 9C) . Furthermore, we found that exogenously added PGE 2 (1-1000 nM) did not induce cell proliferation (not shown).
Finally, incubation of Colon-26 cells with MK886 or baicalein, that respectively inhibit 5-and 12-LOXs, did not alter the effect of mGX sPLA 2 on cell proliferation (Fig. 9D) . Together, these results indicate that although group X sPLA 2 can release large amounts of PGE 2 (and small amounts of other eicosanoids) from Colon-26 cells (Fig. 6 ), this PGE 2 is at best a minor effector of the sPLA 2 proliferative effect. Rather, the sPLA 2 proliferative effect appears to be due to the combined production and direct action of free AA and lysophospholipids including LPC and LPA.
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
This work shows for the first time that group X sPLA 2 can stimulate the proliferation of colon cancer cells and activate the phosphorylation of p42/44 MAPK via its potent catalytic activity and ability to produce various lipid mediators. We found that the proliferative effect of group X sPLA 2 was much higher than that of other mouse sPLA 2 s. This effect was as strong as or higher than that of sPLA 2 -IB, -IIA or -III acting on different cell types (Kinoshita et al., 1997; Sved et al., 2004; Murakami et al., 2005; Belinsky et al., 2007) . mGV and mGIIA sPLA 2 s, but not other enzymes were also able to promote cell proliferation. Except for mGIIA, the ability of the different sPLA 2 s to stimulate proliferation appears to be linked to their direct capacity to hydrolyze phosphatidylcholine and release AA and LPC from cells (Singer et al., 2002; Masuda et al., 2005) . As previously found in LNCaP prostatic cancer cells (Sved et al., 2004) , it is possible that the proliferative effects mediated by mGIIA sPLA 2 is due to activation of cPLA 2 α, but we did not further investigated this point.
The proliferative effect of various sPLA 2 s has been associated with binding to the M-type receptor (Kinoshita et al., 1997) or enzymatic activity of sPLA 2 and subsequent activation of cPLA 2 α (Sved et al., 2004; Murakami et al., 2005) . We found here that the proliferative effect of group X sPLA 2 fully depends on its intrinsic catalytic activity and not on binding to the M-type receptor or cPLA 2 α activation. First, two specific sPLA 2 inhibitors suppressed the proliferative effect of group X sPLA 2 . Second, the H48Q mutants of mGX and hGX sPLA 2 s and the D49K mutant of OS 2 (Rouault et al., 2006) (Fig. 9) . It has been shown that Colon-26 cells express the four PGE 2 receptors (EP1 to EP4), and that PGE 2 is mitogenic on these cells (Pozzi et al., 2004 Based on lysophospholipid analyses of cells treated with hGX sPLA 2 (Fig. 7) , we could estimate that the sPLA 2 can release LPA and LPC at nM and low µM concentrations, respectively.
Although these concentrations are lower than those of exogenously added LPA and LPC (Fig.8) , lysophospholipids produced endogenously may be more effective as they are released locally at the cell surface. The proliferative effect of LPA is likely explained by its binding to receptors LPA1, LPA2 and LPA4 which are expressed in Colon-26 cells (supplemental Fig. 3S ). Whether the proliferative effects of exogenous LPC is due to conversion into LPA by autotaxin (ATX) and subsequent binding to LPA receptors or to a direct action via other G-protein coupled receptors and/or transactivation of tyrosine kinase receptors (Ikeno et al., 2005; Fujita et al., 2006) remains an open question. We analyzed Colon-26 cells for expression of ATX at the mRNA and protein levels (supplemental Fig. 3S ). Although detectable amounts of ATX mRNA were observed by RT-qPCR analysis, no ATX protein could be detected by western-blot analysis using two distinct antibodies and a radioactive lysophospholipase D enzymatic assay . We also analyzed the effect of the recently described ATX inhibitor S32826 on the production of LPA triggered by hGX sPLA 2 in conditions identical to those used in Fig.7 . The ATX inhibitor S32826 had no effect on LPA production at 1 and 10 µM (supplemental Fig. 3S after shuttling into intracellular compartments enriched into PA. Of note, the total amount of LPA released by group X sPLA 2 was less than 3% of the LPC produced (Fig. 7A) , suggesting that the sPLA 2 may have access to little amounts of PA substrate. We have shown that group X sPLA 2 can efficiently hydrolyze PA in mixed phospholipid vesicles (Singer et al., 2002) , but there has been so far no report on the capacity of this enzyme to release LPA from cells. Only a few studies have suggested that group IIA sPLA 2 may be involved in LPA release (Fourcade et al., 1995; Snitko et al., 1997) .
Together, the above data indicate that the proliferative effects of group X sPLA 2 are likely to be dependent on the combined production of both free fatty acids including AA and lysophospholipids including LPC and LPA.
We also found by RT-qPCR that group X sPLA 2 is expressed at very high levels in the small intestine and more particularly in the colon of C57BL/6J and BALB/c mice. The cellular sites of mGX sPLA 2 expression include columnar epithelial cells, Paneth cells and ganglion cells. It should be noted that the very low level of expression measured for mGIIA sPLA 2 mRNA in C57BL/6J mice is due to the natural disruption of the pla2g2a gene. In the small intestine of BALB/c mice harboring a functional gene, the expression level of mGIIA was much higher than those of group X sPLA 2 and other sPLA 2 s (Fig. 1B) . However, the expression of mGIIA dramatically decreased in the colon while that of mGX sPLA 2 increased, making mGX sPLA 2 among the most highly expressed sPLA 2 gene in the proximal and more particularly in the distal colon of both C57BL/6J and BALB/c mice ( Fig. 1A and B). In good accordance, group IIA and X sPLA 2 s are also the most highly expressed sPLA 2 s in human colon . These observations raise the question as to whether the two enzymes play redundant or divergent functions within the small intestine and colon. Based on their unique molecular and functional features, it is likely that the two sPLA 2 s have distinct roles. First, group IIA sPLA 2 is a very basic protein while group X is the most acidic sPLA 2 (Lambeau and Gelb, 2008) . Second, group IIA sPLA 2 binds tightly to anionic phospholipid interfaces but not zwitterionic This article has not been copyedited and formatted. The final version may differ from this version. ones, while group X sPLA 2 shows similar binding (Singer et al., 2002) . Third, their expression in normal intestine is different in both mouse and human species (see above). Fourth, there is a strong upregulation of group IIA sPLA 2 at either mRNA or protein levels in inflammatory bowel diseases and likely in mouse and human colon tumors (Ilsley et al., 2005; Cummings, 2007) . On the other hand, there is no conclusive evidence for upregulation of group X sPLA 2 in the small intestine and colon of Apc ∆ 716 (Takaku et al., 2000) and Apc ∆ 14 mice (supplemental Fig. 2S ), two models of human familial adenomatous polyposis. No upregulation was observed in the colon tumors of mice treated with the carcinogen azoxymethane (Ilsley et al., 2005) and in human colorectal adenocarcinomas (Osterstrom et al., 2002; . This is probably reminiscent of the fact that the catalytic activity of group X sPLA 2 , but not group IIA, may be regulated at the post-translational level by maturation of its N-terminal propeptide by a still poorly defined proteolytic mechanism (Cupillard et al., 1997; Masuda et al., 2005) . Finally, group IIA sPLA 2 likely plays an important antibacterial role in the intestine and is accordingly highly expressed in Paneth cells of the small intestine and epithelial cells of colonic mucosa (Nevalainen et al., 2008) . Its antitumoral role in colon cancer has been proposed to be linked to this antibacterial activity, but the mechanism is still enigmatic (Fijneman and Cormier, 2008) . On the other hand, group X sPLA 2 has been proposed to play a central role in AA release and PGE 2 production in the colon, but not in the small intestine where cPLA 2 α would play the major role (Morioka et al., 2000; Takaku et al., 2000) . This hypothesis fits well with our RT-qPCR data showing a 5-fold higher expression of group X sPLA 2 over cPLA 2 α in the colon, but not in the small intestine (Fig. 1) . Whether autotaxin and/or LPA receptors which are over-expressed in cancer (Parrill and Baker, 2008) contribute to the effects of group X sPLA 2 is unknown. The fact that group X sPLA 2 can produce various lipid mediators suggests that this enzyme may also regulate other key events in tumorigenesis (Wang and Dubois, 2006) . Finally, the presence of mGX sPLA 2 mRNA in ganglion cells may suggest additional functions in the enteric nervous system including neuritogenesis , peristaltic reflex or nociception.
In conclusion, we have shown that group X sPLA 2 can stimulate the in vitro proliferation of colon cancer cells via its enzymatic activity and production of free AA and lysophospholipids. The
This article has not been copyedited and formatted. The final version may differ from this version. high expression of group X sPLA 2 in normal colon and tumors in both mouse and human species and its ability to produce various lipid mediators suggests that this enzyme plays a similar role in vivo.
This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. Although significative (P <0.01), the effect of Me-indoxam was likely due to a toxic effect which was not observed with LY329722 (P>0.05). C. This article has not been copyedited and formatted. The final version may differ from this version. Legend for Supplemental Figures   Fig. 1S . Genotyping of mouse colon cell lines. Genomic DNA was extracted from YAMC, Colon-26, Apc +/Min and AJ02-nm0 mouse colon cell lines and from tails of C57BL/6J and Balb/C mice and subjected to PCR analysis as indicated in supplemental methods. The PCR fragments were analyzed by agarose gel electrophoresis with ethidium bromide staining. Fig. 2S . Expression of group X sPLA 2 and others in mouse models of colon cancer. RNA was isolated from the colon of azoxymethane-treated SWR/J and A/J mice or the colon and ileum of Apc ∆14 mice. The expression of sPLA 2 s, cPLA 2 α, PLA 2 R and COX2 was analyzed by RT-qPCR as described in methods. 2) were loaded under reducing conditions on a 8% SDS-PAGE gel. The presence of ATX was analyzed by western blot using a commercially available rabbit polyclonal ATX-peptide antibody (Cayman Chemicals) or a polyclonal chicken antiserum raised against the recombinant full-length ß isoform of ATX . C, Effect of the ATX inhibitor S32826 on LPA release by hGX sPLA 2 from Colon-26 cells. Cells were treated in conditions identical to those indicated in Fig. 7 in the main text. The ATX inhibitor was preincubated with cells for 15 min at the indicated concentrations before sPLA 2 addition.
